SCHEMBL20139488

SCHEMBL20139488

CCCCC/C=C\CCOC(=O)CCCCCN(CCCCCC(=O)OCC/C=C\CCCCC)CCOCCCCN(C)C

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.54
EPHX2 P34913 4/20 0.48
MGLL Q99685 1/20 0.46
FAAH O00519 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
CNR1 P21554 1/20 0.45
DGKA P23743 2/20 0.44
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCD Q05655 1/20 0.43
PRKCA P17252 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15027019 0.93 DNM1 (0.62) DNM1EPHX2MGLLFAAHALDH1A1
SCHEMBL20141088 0.92 DNM1 (0.62) DNM1EPHX2MGLLFAAHALDH1A1
SCHEMBL20149658 0.89 DNM1 (0.64) DNM1FAAHTHRBDGKA
SCHEMBL25076876 0.88 FAAH (0.50) DNM1EPHX2MGLLFAAHALDH1A1
SCHEMBL24627685 0.87 MGLL (0.59) DNM1MGLLFAAHALDH1A1MAPT
SCHEMBL24493535 0.86 DNM1 (0.62) DNM1EPHX2MGLLFAAHALDH1A1
SCHEMBL20143663 0.85 DNM1 (0.44) DNM1EPHX2
SCHEMBL21380037 0.85 MGLL (0.59) DNM1MGLLFAAHALDH1A1MAPT
SCHEMBL24728585 0.84 EPHX2 (0.57) DNM1EPHX2MGLLFAAHALDH1A1
SCHEMBL17036655 0.84 DNM1 (0.68) DNM1EPHX2MGLLFAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250162978-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF UNIV RAMOT (IL) 2025-05-22 US claimed
US-11851389-B2 Cationic lipids for nucleic acid delivery and preparation thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-12-26 US claimed
EP-3538515-B1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF UNIV RAMOT (IL) 2022-07-20 EP claimed
US-20190292130-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2019-09-26 US claimed
EP-3538515-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF Ramot at Tel-Aviv University Ltd. (IL) 2019-09-18 EP claimed
WO-2018087753-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) 2018-05-17 WO claimed
EP-3538515-B1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF UNIV RAMOT (IL) 2022-07-20 EP disclosed
US-20190292130-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2019-09-26 US disclosed
WO-2018087753-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851389-B2 Cationic lipids for nucleic acid delivery and preparation thereof NPC1L1, NPC1, CETP DNM1 165/4885EPHX2 2483/4885MGLL 138/4885
US-20250162978-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF NPC1L1, NPC1, CETP DNM1 165/4885EPHX2 2483/4885MGLL 138/4885
US-20190292130-A1 CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF NPC1L1, NPC1, CETP DNM1 165/4885EPHX2 2483/4885MGLL 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.